Executive Director Amal Kelshikar tenders resignation, effective 16th October 2026
Torrent Pharmaceuticals has informed the exchanges that Amal Kelshikar, Executive Director designated as Senior Management Personnel, has tendered his resignation, effective from close of business hours on 16th October 2026.
By ScoutQuest · · 2 min read
- Person
- Amal Kelshikar
- Designation
- Executive Director designated as Senior Management Personnel
- Effective date
- 16th October 2026, effective from close of business hours
What was announced
Torrent Pharmaceuticals has informed BSE and NSE that Amal Kelshikar, Executive Director designated as Senior Management Personnel, has tendered his resignation from the post of Executive Director. The resignation is effective from close of business hours on 16th October 2026.
The company has enclosed the details of the change as Annexure-A and a copy of the resignation letter received from him as Annexure-B.
Key details of the change
- Name: Amal Kelshikar
- Designation: Executive Director, designated as Senior Management Personnel
- Reason for change: Resignation from the post of Executive Director
- Effective date: 16th October 2026, effective from close of business hours
- Brief profile and relationships between Directors: Not applicable (the change is a cessation, not an appointment)
What the resignation letter says
In his letter to the Managing Director, Amal Kelshikar writes that he is formally submitting his resignation from the position of Executive Director. He states the decision was made after thoughtful reflection and that, while difficult, he believes it is the right time to transition.
He expresses gratitude to the management and his colleagues for their support, trust and cooperation through his association with the company, including during his extended tenure beyond superannuation. He adds that he remains fully committed to supporting a smooth transition and to completing all handover formalities.
How to read this
This is an intimation of a change in senior management personnel, made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The update records the name of the person, the designation held, the nature of the change and the effective date.
The resignation letter records that the outgoing Executive Director will support the transition and complete handover formalities. For investors, the relevant points to note are the designation involved, the effective date and the transition arrangement described in the letter.
Also from Torrent Pharmaceuticals
Torrent Pharma uploads audio recording of Q2/H1 FY27 results analyst conference call
23 Oct 2026
Consolidated results for the quarter ended 30-Sep-2026 Unaudited
23 Oct 2026
Torrent Pharmaceuticals to hold post Q2/H1 FY27 results conference call with investors and analysts on 23 October 2026
9 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.